ReviewDesigned monomers and polymers2025
A comprehensive insight of innovations and recent advancements in nanocarriers for nose-to-brain drug targeting.
Review in Designed monomers and polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Microglial Activation Under Hypoxic Conditions in Early Alzheimer's Disease: Can Natural SIRT1 Activators Be Therapeutic Allies in the Inflammation-Energy Axis?Phytotherapy research : PTR · 2026Review
- Microglia-Targeted Nanotherapeutics in Major Depressive Disorder: An Integrative Perspective on Neuroinflammation and Drug Delivery.Pharmaceutics · 2025Review
- Naringin and Naringenin in Liver Health: A Review of Molecular and Epigenetic Mechanisms and Emerging Therapeutic Strategies.Antioxidants (Basel, Switzerland) · 2025Review
- Natural Products and Health Care Functions ofCurrent issues in molecular biology · 2025Review
Corrections and comments
- Erratum issuedCorrection.2026
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central Nervous System (CNS) disorders are the leading cause of illness and affect the everyday lives of people all around the globe and are predicted to increase tremendously in the upcoming decades. Traditional methods of delivering drugs to the CNS face considerable limitations. Nose-to-brain targeting offers a promising alternative that bypasses the blood-brain barrier (BBB), enabling targeted drug administration to the central nervous system (CNS). Nanotechnology has brought forward innovative solutions to the challenges of drug delivery in CNS disorders. Nanocarriers such as liposomes, nanoparticles, nanoemulsions and dendrimers can enhance drug stability, bioavailability, and targeted delivery to the brain. These nanocarriers are designed to overcome physiological barriers and provide controlled and sustained drug release directly to the CNS. Nanocarrier technology has made significant strides in recent years, enabling more effective and targeted delivery of drugs to the brain. With recent advancements, intranasal delivery coupled with nanocarriers seems to be a promising combination that can provide better clinical profiles, pharmacokinetics, and pharmacodynamics for neurodegenerative disorders. This study focuses on exploring the nose-to-brain drug delivery system, emphasizing the use of various nanocarriers designed for this purpose. Additionally, the study encompasses recent advancements in nanocarrier technology tailored specifically to improve the efficiency of drug administration through the nasal route to the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.